Log in

NASDAQ:HCMHUTCHISON CHINA/S Stock Price, Forecast & News

$31.52
-0.62 (-1.93 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$31.05
Now: $31.52
$31.88
50-Day Range
$23.00
MA: $27.16
$32.14
52-Week Range
$14.74
Now: $31.52
$32.50
Volume325,642 shs
Average Volume297,774 shs
Market Capitalization$4.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, a c-MET inhibitor for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, a inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; and HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma, as well as HMPL-689, a treatment for indolent non-Hodgkin's lymphoma and healthy volunteers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.
Read More
HUTCHISON CHINA/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HCM
CUSIPN/A
Phone852-2121-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$204.89 million
Book Value$2.75 per share

Profitability

Miscellaneous

Employees714
Market Cap$4.20 billion
Next Earnings DateN/A
OptionableNot Optionable
$31.52
-0.62 (-1.93 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HCM News and Ratings via Email

Sign-up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HUTCHISON CHINA/S (NASDAQ:HCM) Frequently Asked Questions

How has HUTCHISON CHINA/S's stock been impacted by COVID-19 (Coronavirus)?

HUTCHISON CHINA/S's stock was trading at $23.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HCM stock has increased by 36.8% and is now trading at $31.52.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of HUTCHISON CHINA/S?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHISON CHINA/S in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for HUTCHISON CHINA/S
.

What price target have analysts set for HCM?

4 equities research analysts have issued 1-year price targets for HUTCHISON CHINA/S's shares. Their forecasts range from $29.00 to $29.00. On average, they expect HUTCHISON CHINA/S's stock price to reach $29.00 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts' price targets for HUTCHISON CHINA/S
.

Has HUTCHISON CHINA/S been receiving favorable news coverage?

Press coverage about HCM stock has been trending extremely negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. HUTCHISON CHINA/S earned a news impact score of -4.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about HUTCHISON CHINA/S
.

Who are some of HUTCHISON CHINA/S's key competitors?

What other stocks do shareholders of HUTCHISON CHINA/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHISON CHINA/S investors own include Telford Homes (TEF), Premier Oil (PMO), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Crispr Therapeutics (CRSP), Exelixis (EXEL), AT&T (T), Alibaba Group (BABA), Gilead Sciences (GILD) and Johnson & Johnson (JNJ).

Who are HUTCHISON CHINA/S's key executives?

HUTCHISON CHINA/S's management team includes the following people:
  • Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBA, Exec. Chairman (Age 67)
  • Mr. Christian Hogg B.Sc., M.B.A., BSc, MBA, CEO & Exec. Director (Age 53)
  • Mr. Johnny Cheng C.A., BEc, CA, CFO & Exec. Director (Age 52)
  • Dr. Weiguo Su B.Sc., Ph.D., Chief Scientific Officer, Exec. VP & Exec. Director (Age 62)
  • Ms. Edith Shih B.S., M.A., BSE, MA, EdM, Solicitor, FCIS, FCS(PE), Company Sec. & Non-Exec. Director (Age 67)

When did HUTCHISON CHINA/S IPO?

(HCM) raised $100 million in an initial public offering on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHISON CHINA/S's stock symbol?

HUTCHISON CHINA/S trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHISON CHINA/S's major shareholders?

HUTCHISON CHINA/S's stock is owned by a number of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (2.60%), Zeal Asset Management Ltd (1.12%), Sumitomo Mitsui Trust Holdings Inc. (0.36%), UBS Group AG (0.10%), Platinum Investment Management Ltd. (0.08%) and M&T Bank Corp (0.07%).

Which institutional investors are selling HUTCHISON CHINA/S stock?

HCM stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Sumitomo Mitsui Trust Holdings Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, and Janney Capital Management LLC.

Which institutional investors are buying HUTCHISON CHINA/S stock?

HCM stock was bought by a variety of institutional investors in the last quarter, including Zeal Asset Management Ltd, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A., UBS Group AG, Altium Wealth Management LLC, Platinum Investment Management Ltd., Envestnet Asset Management Inc., and SG Americas Securities LLC.

How do I buy shares of HUTCHISON CHINA/S?

Shares of HCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HUTCHISON CHINA/S's stock price today?

One share of HCM stock can currently be purchased for approximately $31.52.

How big of a company is HUTCHISON CHINA/S?

HUTCHISON CHINA/S has a market capitalization of $4.20 billion and generates $204.89 million in revenue each year. The company earns $-106,020,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. HUTCHISON CHINA/S employs 714 workers across the globe.

What is HUTCHISON CHINA/S's official website?

The official website for HUTCHISON CHINA/S is www.chi-med.com.

How can I contact HUTCHISON CHINA/S?

HUTCHISON CHINA/S's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The company can be reached via phone at 852-2121-8200 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.